GMAB Genmab A/S

513.15USD3497.00 DKK · CPH+0.03%Mkt Cap: 31.64B USDP/E: 46.39

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with rel…

Institutional holders11 on file

Key Statistics

Company
Market Cap31.64B USD
Enterprise Value32.97B USD
Revenue (TTM)4.30B USD
Gross Profit3.48B USD
Net Income (TTM)963.00M USD
Revenue/Share69.88 USD
Last Price513.15 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees3.2K
CountryDK
SectorHealthcare
IndustryBiotechnology
ISINDK0010272202
Valuation
P/E (Trailing)46.39
P/E (Forward)29.87
PEG4.65
EV/EBITDA165.69
EV/Revenue7.67
P/S50.19
P/B5.25
EPS (TTM)75.38 USD
EPS (Forward)117.07 USD
52W Range
221.8782% of range579.19
52W High579.19 USD
52W Low221.87 USD
Profitability
Gross Margin93.60%
Oper. Margin30.63%
EBITDA Margin31.56%
Profit Margin25.89%
ROE16.47%
ROA7.48%
ROIC10.46%
ROCE10.92%
Growth
Revenue Growth16.10%
Earnings Growth-14.70%
Cash Flow & Leverage
Operating CF1.19B USD
CapEx (TTM)55.00M USD
FCF Margin19.90%
FCF Yield2.70%
Net Debt3.33B USD
Net Debt/EBITDA2.45
Net Debt/FCF3.89
Balance Sheet
Debt/Equity0.93
Current Ratio2.45
Quick Ratio2.43
Book Value/Sh665.80 USD
Cash/Share29.56 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)615.61 USD
Upside (mean)+20.0%
Target Range469.57 USD – 719.03 USD
469.57+20.0% to mean719.03
# Analysts13
Ownership
Shares Out.61.66M
Float58.96M
Insiders1.12%
Institutions46.39%
Technical
SMA 50410.10 (+25.1%)
SMA 200302.69 (+69.5%)
Beta0.52
S&P 52W Chg12.00%
Avg Vol (30d)184.93K
Avg Vol (10d)171.69K
Technical Indicators
RSI (14)60.8
MACD202.2170
MACD Signal256.5188
MACD Hist.-54.3018
BB Upper605.24 USD
BB Middle514.58 USD
BB Lower423.92 USD
BB Width35.24%
ATR (14)21.03 USD
Vol Ratio (20d)0.52x

About Genmab (CPH: GMAB)

›

Genmab (CPH: GMAB) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 3,244 employees.

The shares were at 3497.00 DKK on 19 November 2026, up 86.5% over 52 weeks. Its 52-week range is 1512.00 DKK to 3947.00 DKK: the price is 11.4% below the high and 131.3% above the low.

At a market capitalisation of 215.62B DKK, it trades at 46.4 times trailing earnings and 29.9 times forward earnings. The median trailing P/E of its 12 largest Biotechnology peers is 33.1, a premium of 40% for GMAB.

Genmab reports return on equity of 16.5%, an operating margin of 30.6% and revenue up 16.1% year over year.

Its debt exceeds its cash by 3.33B USD, a debt-to-equity ratio of 0.93. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 13 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 4195.23 DKK is 20.0% above the current price. The next earnings report is expected on 16 February 2027.